About TheraVida
TheraVida is a company based in San Mateo (United States) founded in 2005. TheraVida has raised $12.5 million across 5 funding rounds from investors including Sanderling Ventures. TheraVida offers products and services including Anhydrix. TheraVida operates in a competitive market with competitors including Esprit Pharma, Lipella, Regenfro Co, Kissei Pharmaceutical and NEXT Life Sciences, among others.
- Headquarter San Mateo, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Theravida, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.5 M (USD)
in 5 rounds
-
Latest Funding Round
$200 K (USD), Debt – Conventional
Feb 21, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TheraVida
TheraVida offers a comprehensive portfolio of products and services, including Anhydrix.
Treatment for primary focal hyperhidrosis with improved tolerability.
Funding Insights of TheraVida
TheraVida has successfully raised a total of $12.5M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $200 thousand completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TheraVida
TheraVida has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Sanderling Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical investment financing and active management services.
|
Locked | Locked | Locked |
Investor details for TheraVida
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TheraVida
Investment portfolio details for TheraVida
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TheraVida
Detailed financials for TheraVida
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Theravida Comparisons
Peer comparison for TheraVida
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TheraVida
TheraVida operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Esprit Pharma, Lipella, Regenfro Co, Kissei Pharmaceutical and NEXT Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develop drugs for genitourinary (GU) disorders
|
|
| Locked | Locked | Locked |
Lipid-based therapies for common bladder syndromes are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat renal diseases
|
|
| Locked | Locked | Locked |
Therapies for renal diseases and urology-related anemia are developed.
|
|
| Locked | Locked | Locked |
Male contraception procedures are developed via Vasalgel technology.
|
Detailed competitors of TheraVida
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Theravida
Complete news archive for TheraVida
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TheraVida
TheraVida was founded in 2005 and raised its 1st funding round 2 years after it was founded.
TheraVida is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
TheraVida is a funded company, having raised a total of $12.5M across 5 funding rounds to date.
TheraVida was founded in 2005 in San Mateo, United States, as a clinical-stage biopharma entity. Focus is placed on developing treatments for overactive bladder, urge urinary incontinence, and primary focal hyperhidrosis. The lead product, Tolenix (THVD-201), is designed to minimize dry mouth side effects in overactive bladder therapy. Phase III studies are underway for overactive bladder and urinary incontinence, while Phase II trials address hyperhidrosis.
TheraVida's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
TheraVida offers Anhydrix.
TheraVida has 1 investor. Key investors include Sanderling Ventures.